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This study evaluates the usefulness of PET for the preoperative
evaluation of brain gliomas and methods of quantification of PET
results. Methods: Fifty-four patients with brain gliomas were studied
by PET with 18F-fluorodeoxyglucose (FDG) (n = 45) and/or 11C-
methionine (MET) (n = 41) before any treatment. Results of visual
analysis, calculation of glucose consumption and five tumor-to-
normal brain ratios for both tracers were correlated with two
histologie grading systems and with follow-up. Results: Visual
analysis (for FDG) and tumor-to-mean cortical uptake (T7MCU) ratio
proved to be the best tools for the evaluation of PET results.
Methionine was proven to be better than FDG at delineating low-
grade gliomas. Tumor-to-mean cortical uptake ratios for FDG and
MET were clearly correlated (r = 0.78), leading to the equation
T/MCUFDG = 0.4-T/MCUMET. We showed a good correlation be
tween FDG PET and histologie grading. MET uptake could not
differentiate between low-grade and anaplastic astrocytomas but
was significantly increased in glioblastomas. Low-grade oligoden-
drogliomas exhibited high uptake of FDG and MET, probably
depending more on oligodendroglial cellular differentiation than on
proliferative potential. Uptake was decreased in anaplastic oligoden-
drogliomas, probably due to dedifferentiation. Care must be taken
with peculiar histologie subgroups, i.e., juvenile pilocytic astrocyto
mas and oligodendrogliomas, because of a discrepancy between
high PET metabolism and low proliferative potential (good progno
sis). Both tracers proved useful for the prediction of survival prog
nosis. Methionine proved slightly superior to FDG for predicting the
histologie grade and prognosis of gliomas, despite the impossibility
of differentiation between Grades II and III astrocytomas with MET.
This superiority of MET could be explained by patient sampling (low
number of Grade III gliomas submitted to examination with both
tracers). The combination of both tracers improved the overall
results compared to each tracer alone. Conclusion: Both tracers
are useful for the prediction of the histologie grade and prognosis.
The apparent superiority of MET over FDG could be due to the small
number of Grade III gliomas studied with both tracers.
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.Tor a few years, PET has been used for evaluation of brain
tumors (detection of a tumor, prediction of the histologie grade
of gliomas, prediction of prognosis, evaluation of response to
treatment and differential diagnosis between recurrence and
radiation necrosis) (1-11). The most widely used tracer is
certainly fluorine-18-fluorodeoxyglucose (FDG). A method of
absolute parametric quantification is available for this tracer,
which might be seen as an advantage. FDG is, however, a
nonspecific tracer, which sometimes limits its interest. For
Received May 2, 1997; revision accepted Aug. 5, 1997.
For correspondence or reprints contact: Bruno Kaschten, MD, Department of
Neurosurgery, C.H.U. Sart-Tilman (B35), B-4000 LiÃ¨ge,Belgium.
example, low-grade gliomas are usually seen as hypometabolic
lesions that are undistinguishable from other pathologies, such
as ischemie lesions. Carbon-11 -methionine (MET), an amino
acid, might be better to detect these low-grade tumors. Both
tracers have advantages and limitations, but only a few centers
have published comparative results using both tracers in small
series of patients with gliomas (12-14) (Table 1). Combined
studies on larger groups of patients are necessary to determine
which is the best tracer to use for the specific clinical problem.
Moreover, the combination of both tracers can give valuable
indications concerning the metabolism and the rate of expan
sion of these tumors.
In some previous reports, relationships were found between
FDG uptake and the histologie grade of gliomas (1,3,9,13), the
tumor cell density (75) and the survival prognosis (5,7,16,17).
Correlations also were demonstrated between MET uptake and
histology (6,13,14,18,19), but so far no correlation has been
demonstrated between MET uptake and survival prognosis.
Most of the published large series included heterogeneous
groups of patients, some evaluated before treatment and others
studied after treatments such as radiation therapy or chemother
apy, which certainly modify the metabolism of the normal brain
as well as of the tumor tissue. The preoperative prediction of
histologie grade or survival prognosis requires objective crite
ria. Consequently, from a series of about 300 PET examinations
of brain gliomas performed in our center, we selected 54
patients (86 PET examinations) who were evaluated before any
treatment that could have interfered with the metabolism,
except for corticoids (20) or antiepileptic drugs (21-23).
There is no consensus on the best method to analyze PET
studies in patients with gliomas. We have, therefore, evaluated
our PET examinations according to several methods described
in the literature, to compare their usefulness in clinical practice.
MATERIALS AND METHODS
Patients
We evaluated 54 patients (28 men and 26 women) with sus
pected brain gliomas before they had received any treatment. PET
examinations were performed on 13 patients with FDG alone, on 9
patients with MET alone and on 32 patients with both tracers.
Mean age was 50 Â±17 yr (age range 12.8-74.9 yr). Time from
first symptoms to surgery ranged from 0.4 mo to 10 yr (mean
age =11.5 mo).
Pathologic diagnosis was obtained by open surgery (n = 40) or
stereotactic biopsy (n = 9). In five patients in which no pathologic
examination was obtained, the diagnosis of low-grade astrocytoma
(4 patients) or low-grade oligodendroglioma (1 patient exhibiting
calcifications on CT) was based on radiologie investigations and
confirmed by the clinical follow-up (all patients stable without any
treatment). All available specimens were reviewed by two neuro-
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TABLE 1
Previously Published Series Comparing PET with Glucose and MET in Brain Tumors
First author(Ref.)Ericson
(72)Ogawa
(73)Derlon
(74)No.
of patients
(no. ofgliomas)16(14)11(9)22Tracers11C-MET11C-glucose"C-MET18F-FDG"C-MET18F-FDGCorrelationwithhistologyNot
studiedNot
studiedYesYesYes-Yes*Correlation
withsurvivalNot
studiedNot
studiedNot
studiedNot
studiedNot
studiedNot
studied
'Correlation with histologie type (astrocytoma compared to oligodendroglioma) but not with histologie grade (included only low-grade gliomas).
pathologists according to the World Health Organization (WHO)
(24) and Mayo-Sainte Anne (25) classifications.
According to the WHO classification (n = 54), the distribution
of specimens was as follows: I juvenile pilocytic astrocytoma
(JPA; Grade I), 23 low-grade (Grade II) gliomas, 10 anaplastic
(Grade III) gliomas and 20 glioblastomas (Grade IV). Grade II and
III gliomas were divided into three subgroups: astrocytomas
(Group A), oligodendrogliomas (Group O) and mixed oligoastro-
cytomas (Group OA) (Table 2). According to the Mayo-Sainte
Anne classification (n = 49 because the five patients without
surgical histology were not included), there were 2 Grade I, 18
Grade II, 6 Grade III and 23 Grade IV gliomas.
The 32 patients submitted to PET examination with both tracers
included 1 JPA, 19 WHO Grade II gliomas (12 Group A, 5 Group
OA and 2 Group O), only 2 Grade III gliomas (1 Group OA and 1
Group O) and 10 Grade IV astrocytomas (glioblastomas). The
relative lack of Grade III gliomas and its influence on the results is
discussed below.
In most patients (n = 44), PET was performed within a few days
before surgery. In five patients with low-grade gliomas, the time
between PET and surgery ranged from 2-8 mo, without clinical or
radiologie evidence of tumor modification during this time. In the
five patients without pathologic verification, the day of PET
examination was considered the reference for the follow-up.
Postoperatively, 37 patients were treated by radiation therapy,
and 1 patient was treated by brachytherapy. At time of recurrence,
6 patients underwent reoperation (4 resections and 2 biopsies), 1
patient received radiation therapy and 10 patients were treated by
chemotherapy with carmustine. Follow-up ranged from 1 to 86 mo
(mean follow-up = 18 mo). At time of completion of this study, 25
patients were dead: 3 with Grade II astrocytomas, 6 with Grade III
astrocytomas and 16 with Grade IV astrocytomas (glioblastomas).
PET Methods
The first PET examinations (16 patients) were performed with a
NeuroEcat tomograph (EG&G ORTEC, Oak Ridge, TN) (intrinsic
resolution = 8 mm FWHM), providing only two simultaneous
slices in high-resolution mode. Since 1992 (38 patients), PET
examinations have been performed with a Siemens ECAT 951/31R
camera (CTI PET Systems, Inc., Knoxville, TN), imaging 31
TABLE 2
Pathologic Results According to WHO Classification (n = 54)
Grade1IIIIIIVNo.
ofastrocytomas(Group
A)116620No.
ofoligoastrocytomas(Group
OA)51No.
ofoligodendrogliomas(Group
O)23
planes simultaneously over an axial length of 10.8 cm (resolu
tion = 6 mm FWHM).
Patients fasted for at least 4 hr before the PET examination. PET
images were acquired with the patients in a resting state, with their
eyes closed and with minimum ambient noise. Imaging planes were
oriented parallel to the canthomeatal line. In 54 PET examinations,
transmission images first were obtained to correct for photon
attenuation; in 32 PET examinations, attenuation correction was
performed with a skull-fitting, operator-drawn ellipse method. A
dose of 222-370 MBq (6-10 mCi) FDG or 481-740 MBq (13-20
mCi) MET was injected intravenously within 1 min. Static emis
sion scanning was performed for a 20-min period, beginning at
least 10 min after MET injection or at least 30 min after FDG
injection. In 30 patients, arterial blood samples obtained after FDG
injection allowed the calculation of the cerebral metabolic rate of
glucose (CMRG1; in mg/100 g/min) of the tumor, after the method
of Sokoloff et al. (26) and the operational equation derived by
Phelps et al. (27).
When both tracers were injected into the patient on the same day
(n = 24), MET PET was performed first, considering the short
half-life of "C (20 min), and FDG PET then was performed after
a sufficient time had elapsed to allow for UC decay (at least five
periods or 100 min).
Data Analysis
In all cases, CT and MRI data were available during PET
examination and during evaluation and quantification of the results.
Fusion of MRI images over PET data was used only recently for
the last patients.
Images were first evaluated by comparison with the surrounding
brain parenchyma [regardless of whether it was cortex (CTX) or
white matter (WT)] and classified as follows:
1. +, hypermetabolic lesion (hot spot);
2. â€”,hypometabolic lesion (cold spot); and
3. O, lesion difficult to distinguish from surrounding brain
tissue.
Lesions were then rated by visual analysis according to Schifter et
al. (16):
1. Grade I, uptake by the tumor lower than that of WM;
2. Grade II, uptake equal to that of WM;
3. Grade III, uptake between those of WM and CTX;
4. Grade IV uptake equal to that of CTX; and
5. Grade V, uptake higher than that of CTX.
Raw appearance of the lesion (hot or cold spot) and visual grading
according to Schifter et al. (16) are two separate methods of
evaluation, the latter depending on the location of the lesion. A
tumor with an intermediate FDG uptake, between those of WM and
CTX [visual Grade III by Schifter et al. (76)] may be a hot spot in
WM as well as a cold spot in the CTX or basal ganglia.
When available, CMRG1 was calculated as described above.
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TABLE 3
PET Results with Fluorine-18-FDG
Grade/typeI
(n =1)II
(n =23)Astrocytoma
(n =16)Oligoastrocytoma
(n=Oligodendroglioma
(nIII
(n =6)Astrocytoma
(n =3)Oligoastrocytoma
(n=Oligodendroglioma
(nIV
(n = 15)5)=
2)1)=
2)T/CTX0.840.59
Â±0.250.54
Â±0.220.56
Â±0.221.01
Â±0.190.71
Â±0.270.89
Â±0.150.840.39
Â±0.021.28
Â±0.42T/CCR1.290.79
Â±0.420.76
Â±0.450.75
Â±0.361.1
3Â±0.450.85
Â±0.160.95
Â±0.170.840.72
Â±0.021.90
Â±0.98RatioT/MCU0.860.55
Â±0.220.51
Â±0.200.51
Â±0.150.98
Â±0.110.77
Â±0.280.92
Â±0.141.000.43
Â±0.001.23
Â±0.43T/WM1.541.1
5Â±0.461.11
Â±0.501.09
Â±0.341.58
Â±0.091.57
Â±0.661.76
Â±0.662.230.96
Â±0.042.62
Â±1.02T/W*C1.220.75
Â±0.310.70
Â±0.290.72
Â±0.211.28
Â±0.061.03
Â±0.341.21
Â±0.271.260.66
Â±0.011.72
Â±0.50CMRGI
(mg/1 00g/min)3.51
Â±0.433.32
Â±0.982.91
Â±0.887.504.88
Â±1.875.39
Â±0.827.293.1
6Â±1.036.10
Â±1.77
Values are mean Â±s.d.
Finally, five ratios were calculated for each tracer between the
uptake of the tumor [region of interest (ROI) placed in the region
of highest uptake)] and various normal brain tissue references:
1. T/CTX ratio, tumor-to-contralateral CTX in front of the
tumor ratio;
2. T/CCR ratio, tumor-to-same contralateral corresponding re
gion ratio;
3. T/MCU ratio, tumor-to-mean cortical uptake (seven ROls)
ratio;
4. T/WM ratio, rumor-to-WM (two ROIs in the centrum semi
ovale) ratio; and
5. T/W*C ratio, tumor-to-mean uptake of WM (centrum semi
ovale) and temporal CTX ratio.
The ROI diameter was chosen depending on the size and aspect
of the tumor on CT, MRI and PET images. When the rumor was
large and homogeneous, the ROI was two times the spatial
resolution of the tomograph. In small tumors or when only a thin
rim of viable tissue surrounded a cystic or necrotic center, a smaller
ROI was used to include, to the highest extent possible, only viable
tumoral tissue.
Statistical analysis included multiple-group comparisons by
analysis of variance, comparisons between histologie subgroups by
Student's t-test, comparisons between FDG and MET ratios by
linear regression, comparisons of the different ratios and of the two
tracers by stepwise multigroup logistic discriminant analysis and
survival analysis by Cox's model and the life-table method of
Kaplan and Meier.
RESULTS
The results of FDG PET and MET PET examinations are
presented in Tables 3 and 4, according to the histologie grades
and types of the WHO classification. For some patients, T/CCR
ratio (four tumors on the midline) or CMRGI was not available.
Considering the peculiar metabolic behavior of the single case
of JPA (Grade I), correlations described below, if not specified,
are reported for Grades II, III and IV gliomas. In some
statistical analyses, astrocytomas and oligoastrocytomas were
grouped together.
Visual Analysis
Raw appearance of the lesion (hot or cold spot) and visual
grading according to Schifter et al. (16) are combined in Table
5. In most low-grade tumors (Fig. 1), FDG PET showed a
hypometabolic focus (Table 5, â€”), and visual grade usually
extended from 1 to 3. In most high-grade tumors (Fig. 2), FDG
PET showed a hypermetabolic focus (Table 5, +), and visual
grade usually extended from 3 to 5. However, these usual
findings have to be tempered in some cases. Some low-grade
gliomas exhibited a hot spot, especially JPAs (Grade I) and
oligodendrogliomas. In Grade III tumors, oligodendrogliomas
exhibited a cold spot and visual grades of 1 to 2. Finally, four
glioblastomas were rated only visual Grade III because of large
necrotic or cystic center surrounded by only a thin rim of
tumoral viable tissue (partial volume effect), but all presented
nevertheless as hot spots on the images. FDG visual grade was
clearly correlated to WHO histologie grade (p < 0.001).
Concerning MET PET, all but two lesions were clearly
TABLE 4
PET Results with Carbon-11-MET
Grade/typeI
(n =1)II
(n =19)Astrocytoma
(n =12)Oligoastrocytoma
(n=Oligodendroglioma
(nIII
(n =6)Astrocytoma
(n =3)ONgoastrocytoma
(n=Oligodendroglioma
(nIV
(n = 15)5)=
2)1)=
2)T/CTX1.751.71
Â±0.601.47
Â±0.301.81
Â±0.722.88
Â±0.162.08
Â±0.711.56
Â±0.163.342.22
Â±0.252.81
Â±0.61T/CCR2.421.94
Â±0.741.73
Â±0.511.89
Â±0.853.16
Â±0.062.05
Â±0.771.48
Â±0.303.342.27
Â±0.193.09
Â±0.59RatioT/MCU1.781.64
Â±0.621.39
Â±0.291.73
Â±0.682.91
Â±0.341.98
Â±0.621.54
Â±0.283.062.12
Â±0.062.79
Â±0.71T/WM3.282.58
Â±0.942.26
Â±0.472.61
Â±1.054.43
Â±0.872.85
Â±0.892.28
Â±0.014.582.85
Â±0.114.37
Â±1.41T/WC2.542.09
Â±0.791.78
Â±0.342.18
Â±0.853.71
Â±0.742.40
Â±0.731.87
Â±0.303.652.58
Â±0.093.51
Â±1.00
Values are mean Â±s.d.
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TABLE 5
Results of Visual Analysis for FDG PET According to WHO Histologie Grading
(WHO)1 2345
II Astrocytoma
Oligoastrocytoma
Oligodendroglioma
III Astrocytoma
Oligoastrocytoma
Oligodendroglioma
IV
+
O+
+
depicted as hot spots on the images, allowing a more precise
delineation of the tumor than with FDG, especially in low-grade
gliomas. All patients except four of them were rated Grade V,
indicating that this visual grading method was useless for MET
PET (not correlated to the histologie grade).
Multiple-Group Comparisons
Taking all the WHO grades together and considering either
all types of gliomas, only astrocytomas or astrocytomas and
oligoastrocytomas, analysis of variance showed significant
differences for all the variables (p < 0.001 for FDG and MET)
except visual analysis of MET. Results were slightly less
significant with the Mayo-Sainte Anne classification (p < 0.01
for FDG; p < 0.05 for MET except visual analysis).
FIGURE 1. Grade II astrocytoma. MPI (T1-weighted image after gadolinium
injection) showing hypointense lesion with a small region of contrast en
hancement. PET showing increased uptake of MET and decreased uptake of
FDG in the tumor.
FIGURE 2. Glioblastoma (Grade IV). MRI (T1-weighted image after gadolin
ium injection) showing necrotic lesion with heterogeneous contrast enhance
ment. PET showing high uptake of both MET and FDG in the tumor.
Comparisons between Groups A, OA and O within either
Grade II or Grade III gliomas snowed significant differences for
FDG (p < 0.05) and MET (p < 0.01), except for visual analysis
of MET.
Comparisons Between Histologie Subgroups
FDG PET showed significant differences between Grades II
and III gliomas (p < 0.05 for T/MCU and T/W*C) and more
significant differences between Grades III and IV gliomas (p <
0.001 for T/CTX, p < 0.01 for T/W*C and p < 0.05 for the
other ratios; p was not significant for CMRG1). Differences
were highly significant between Grades II and IV gliomas (p <
0.001 for all the variables, including CMRG1).
When only astrocytomas or astrocytomas and oligoastrocy
tomas were considered, differences were significant between
Grades II and III (p < 0.001) and between Grades II and IV
gliomas (p < 0.001 ) but not between Grades III and IV gliomas
because of the large s.d. for glioblastomas.
MET PET results were the same considering either all
gliomas, only astrocytomas or astrocytomas and oligoastrocy
tomas. There was no difference between Grades II and III, but
there were highly significant differences between Grades II and
IV (p < 0.001 for all ratios) and between Grades III and IV
gliomas (p < 0.001 to p < 0.05, depending on the ratios).
Oligodendrogliomas paradoxically exhibited a higher uptake
of FDG and MET in Grade II than they did in Grade III gliomas.
The Grade IJPA had a behavior closer to that of the Grade III
astrocytomas than to that of the Grade II tumors, with a high
uptake of FDG as well as of MET.
According to the Mayo-Sainte Anne classification, consid
ering either all types of gliomas, only astrocytomas or astrocy
tomas and oligoastrocytomas, FDG PET showed significant
differences between Grades I and III (p < 0.02) and between
Grades II and IV gliomas (p < 0.001), whereas MET PET
showed only a statistically significant difference between
Grades II and IV gliomas (p < 0.001).
For all the variables, there was no significant difference
between astrocytomas and oligoastrocytomas within each
grade, although oligoastrocytomas exhibited a slightly higher
uptake of MET than did astrocytomas.
Grade II (WHO) oligodendrogliomas exhibited a higher
metabolism than did Grade II astrocytomas, considering either
FDG (p < 0.02) or MET (p < 0.001). In Grade III tumors,
uptake of FDG was lower in Grade III oligodendrogliomas than
it was in Grade III astrocytomas (p < 0.02), but uptake of MET
remained higher in Grade III oligodendrogliomas than they did
in Grade III astrocytomas (p < 0.05), although it was lower
than that in Grade II oligodendrogliomas.
The same calculations, after exclusion of cases without
pathologic verification, brought the same statistical significance
and will not be detailed here.
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TABLE 6
Correlation Between FDG and MET (n = 32),
Linear Regression Analysis
Ratio
T/MCUT/W*CT/WMT/CTXT/CCR0.77540.75670.70790.68250.5693<0.001<0.001<0.001<0.001<0.01
Correlation Between FDG and MET Ratios
Considering patients submitted to PET examination with both
tracers (n = 32), linear regression analysis was applied to the
corresponding ratios (Table 6). The best correlation was ob
served with T/MCU ratio (r = 0.78, p < 0.001) (Fig. 3), from
which the following equation could be derived:
T/MCUFDG = 0.4 â€¢T/MCUMET.
The ranges of the T/MCU ratio were 0.30-2.12 for FDG PET
and 0.70-5.05 for MET PET.
Discriminant Power of the Ratios
Stepwise multigroup logistic discriminant analysis was used
to select, for each tracer, the best ratio(s) for clinical purpose,
based on their discriminant power (capacity to reclassify pa
tients in the correct histologie grade from the PET results).
When all WHO Grades II, III and IV gliomas were consid
ered, the most discriminant ratios for FDG were the T/W*C,
T/CTX and T/MCU ratios alone [82% correct classification],
and the most discriminant ratio for MET was the T/MCU ratio
(69%). When astrocytomas and oligoastrocytomas were consid
ered, the most discriminant ratios were the T/W*C and T/MCU
ratios (86% correct classification) and the T/MCU ratio (81%
correct classification), for FDG and MET, respectively.
When only the Grades II and IV astrocytomas were consid
ered (the number of Grade III astrocytomas was too small to be
considered), the most discriminant ratios were the T/WM,
T/W*C and T/MCU ratios (96% correct classification) for
FDG, whereas for MET, all ratios except the T/correct classi-
ficationR ratio gave 100% correct classification due to total
separation of the two groups.
Considering the Grades II, III and IV of the Mayo-Sainte
Anne classification, the most discriminant variables were the
T/WM ratio (80% correct classification) and the T/MCU ratio
(74% correct classification) for FDG and MET, respectively.
T/MCU-FDG - 04 T/MCU-MET
Gradel
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2 3
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FIGURE 3. Linearregressionof the T/MCUFDG ratio over the T/MCUMEr ratio,
correlated with histologie grade of WHO classification (r = 0.78, p < 0.001).
FIGURE 4. Survival curves (Kaplan-Meier analysis)according to FDG visual
grade (FDG-AV) (p < 0.001).
Discriminant Power of MET Compared with FDG
The same stepwise analysis was applied to the T/MCUFDG
and T/MCUMET ratios together to select which of the tracers
was the most discriminant, considering the prediction of the
histologie grade. The choice of the T/MCU ratio was derived
from the results described above.
When considering all Grades II, III and IV gliomas (WHO),
the most discriminant was the T/MCUMET ratio (71% correct
classification, p < 0.001 ). Addition of the T/MCUFDG ratio was
at the limit of statistical significance (p = 0.08) and improved
the results to 81% correct classification.
When astrocytomas and oligoastrocytomas were considered,
results were similar: MET was the most discriminant tracer
(86% correct classification, p < 0.001), and addition of FDG
improved the results to 89% correct classification (p = 0.06).
When only Grades II and IV astrocytomas were considered,
MET remained the most discriminant because of complete
separation between the two groups (100% correct classifica
tion). FDG did not improve the results.
When only Grades II, III and IV (Mayo-Sainte Anne) were
considered, MET was also the most discriminant (80% correct
classification, p < 0.001), and addition of FDG improved the
results to 88% correct classification (p = 0.14).
Survival Analysis
Cox's model was used to analyze the correlation between the
different parameters (tumor-to-normal brain ratios and CMRG1)
and survival. For FDG the most significant prognostic factor
was the T/CTX ratio (p < 0.001). The stepwise procedure gave
no further significant variable. For MET the most significant
variable was the T/MCU ratio (p < 0.001). The stepwise
procedure did not give any further significant variables.
Prognostic significance of MET compared to FDG was
assessed by using a Cox's model with the T/MCUFDCi and
T/MCUMET ratios. The T/MCUMET ratio proved the most
significant (p < 0.001), and the stepwise procedure gave no
further value, indicating that addition of FDG did not bring
more prognostic power over MET alone.
The life-table method of Kaplan and Meier was then used to
assess the prognostic role of visual analysis (for FDG) and of
the T/MCU ratio (for both tracers) (this ratio was selected
considering all the results described above).
There was a significant correlation (p < 0.001) between
visual analysis of FDG PET and survival (Fig. 4): prognosis
was very good for visual Grades I and II (median survival > 5
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T/MCU-FDGÂ«0.8
0.8<T/MCU-FOG<1.1
T/MCU-FDG Â»1.1
40 60
Time(monthÂ»)
100
FIGURE 5. Survivalcurves (Kaplan-Meier analysis)according to T/MCUFDG
ratio (p < 0.001).
yr), fair for visual Grade III (median survival = 31 mo) and bad
for visual Grades IV and V (median survival = 10 mo).
Patients were divided into three groups according to the
T/MCU ratio for FDG: highly significant differences (p <
0.001) were observed between the 23 patients with a
T/MCUFDG ratio of <0.8 (median survival > 5 yr), the 12
patients with T/MCUFDG ratios between 0.8 and 1.1 (median
survival = 20 mo) and the 10 patients with T/MCUFDG ratios of
>1.1 (median survival = 10 mo) (Fig. 5).
Considering the previous results for MET PET and the
absence of differentiation between Grades II and III gliomas,
patients were divided into only two groups: prognosis of the 21
patients with T/MCUMET ratios of <2.1 (median survival > 5
yr) was significantly better than prognosis of the 20 patients
with T/MCUMFT ratios of >2.1 (median survival = 8 mo) (Fig.
6) (p < 0.001);
Figure 7 shows the survival curves when FDG and MET are
considered together: prognosis was good when the uptake was
low for both tracers, fair when there was a high uptake of one
of the tracers and bad when there was a high uptake of both
tracers (p < 0.001).
DISCUSSION
Methods of Interpretation of PET Results
The simple visual analysis of FDG PET offers a reliable
estimation of tumor grading and prognosis. Gliomas with FDG
uptake lower than or equal to that of the WM have a good
T/MCU-MET < 2.1
T/MCU-MET>2.1
40
Time (monthÂ»
T/MCU-FDG < 08 and T/MCU-MET < 21
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0.8 < T/MCU-FDG < 1.1 and T/MCU-MET < 2.1
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T/MCU-FDG > 1 1 and T/MCU-MET > 2 1
40
Time (monthÂ»)
FIGURE 6. Survival curves (Kaplan-Meier analysis) according to T/MCUMET
ratio (p < 0.001).
FIGURE 7. Survival curves (Kaplan-Meier analysis) according to both
T/MCUFDG and T/MCUMET ratios (p < 0.001).
prognosis; those with FDG uptake between those of WM and
CTX have an intermediate prognosis; whereas prognosis is poor
when FDG uptake is equal to or greater than that of CTX.
Nearly all our patients exhibit a MET uptake higher than that
of CTX, which does not allow histologie grading based only on
visual analysis, but have the advantage of precisely delineating
the tumors, especially low-grade gliomas in which FDG usually
cannot differentiate between tumor and surrounding edema.
Image registration (fusion of MRI and PET images) is now
available and greatly increases the accuracy of interpretation of
PET data, especially for FDG PET.
Calculation of tumor-to-normal brain tissue ratios is a very
simple semiquantitative method allowing comparisons between
groups of individuals or between repeated PET examinations of
the same patient. Trying to solve the problem of standardization
of the results, we showed that the less useful ratio was
obviously the T/CCR ratio: it cannot be applied to tumors of the
midline and has the largest variability due to the contralateral
reference (sometimes CTX, sometimes WM and often a com
bination of both). Considering all the statistical results de
scribed above, the T/MCU, T/CTX and T/W*C ratios are all
satisfactory ratios for evaluating FDG PET, but the T/MCU
ratio seems to have important advantages for MET interpreta
tion, as demonstrated in the stepwise multigroup logistic dis
criminant analysis. Moreover, the T/MCU ratio is the more
reproducible between PET centers and is only subject to a low
error margin because it is calculated as a mean of seven cortical
regions (medial and lateral frontal, medial and lateral temporal,
parietal, medial and lateral occipital CTX). We suggest that the
T/MCU ratio should be used as a standardized reference for
evaluation of PET results with both FDG and MET.
Absolute quantification of glucose consumption (CMRG1) is
interesting for research purposes but less useful in clinical
practice because of large variations in tumoral CMRG1 as well
as in normal brain tissue. Statistical results were less significant
with this parameter than with tumor-to-normal brain ratios. It
remains interesting for comparisons of iterative PET examina
tions in the same patient, for instance, in the evaluation of
response to radiation therapy and/or chemotherapy. However,
as already stated by Di Ghiro and Brooks (28), considering its
heaviness, it cannot be recommended as a routine procedure.
Correlation Between PET Results and Histology
Although not always statistically significant because of the
low number of patients in some groups, FDG uptake increases
progressively with malignancy from Grade II to Grade IV
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gliomas, especially in pure astrocytomas. Oligoastrocytomas
have the same FDG PET pattern as do astrocytomas, regardless
of whether Grade II or Grade III tumors are considered.
MET PET did not allow differentiation between Grade II and
Grade III gliomas, especially in astrocytomas; MET uptake was
significantly higher in glioblastomas. Despite the low number
of cases, the higher MET uptake in our oligoastrocytomas
compared with pure astrocytomas confirms the results of
Ericson et al. (12) (three oligoastrocytomas with marked accu
mulation of MET).
Pure oligodendrogliomas seem to exhibit different behavior.
Derlon et al. (14), in low-grade gliomas, showed a significantly
higher uptake of MET in oligodendrogliomas than in astrocy
tomas, whereas both histologie types exhibited FDG hypome-
tabolism, which was slightly more pronounced in astrocytomas.
We confirm that Grade II oligodendrogliomas have a higher
uptake of MET and FDG than do Grade II astrocytomas or
oligoastrocytomas, probably reflecting some specific metabolic
properties of oligodendroglial cells (such as myelin synthesis)
rather than proliferative tumoral metabolic activity; this could
explain the discrepancy between high metabolic activity and
good prognosis. This difference could also be explained by
different cellular densities or rates of cell turnover (14).
Moreover, the decreased metabolism in Grade III compared to
Grade II oligodendrogliomas could reflect the cellular dediffer-
cntiation accompanying anaplasia, decreasing specific "oligo
dendroglial" metabolism, whereas proliferative tumoral metab
olism is not really increased. The low FDG uptake, lower than
in Grade III astrocytoma, corresponds to the good prognosis of
Grade III oligodendrogliomas (100% alive in our series) com
pared with Grade III astrocytoma (100% dead in our series).
However, although decreased compared to Grade II oligoden-
droglioma, MET uptake in Grade HI oligodendroglioma re
mains higher than in Grade III astrocytoma.
Our JPA patient also presents a discrepancy between a quite
high metabolism (FDG and MET) and a good prognosis.
Fulham et al. (29) reported similar observations in a series of
five JPAs studied with FDG. Patients with JPA also can exhibit
pseudomalignant radiologie features, such as contrast enhance
ment on CT and MRI. These findings might reflect the unusual
vascularity of JPA, and the increased FDG uptake might be
related to marked expression of the glucose transporter (29).
However, the increased MET uptake demonstrated in our case
could indicate a really peculiar metabolic property rather than
just a difference in vascularity.
Correlation of our PET results with pathologic grading
according to Mayo-Sainte Anne classification did not give
additional information. From our point of view, it is less useful
than the WHO classification.
Correlation Between FDG and MET Uptakes
Ogawa et al. (13) first demonstrated a correlation between
CMRG1 and MET uptake. In our series, linear regression
showed significant correlation between FDG and MET for all
the ratios used, especially for the T/MCU ratio.
When the T/MCUFDG ratio is divided by the T/MCUMET
ratio, the values obtained fluctuate greatly between 0.19 and
0.68 (mean = 0.4, as described above); no significant difference
could be observed in this correlation either between histologie
grades or between histologie subgroups.
Correlation Between PET Results and Survival
The prognostic significance of FDG PET has been recog
nized since the works of Di Ghiro and his group and has been
confirmed by other groups (3,5,7,16,17). To our knowledge, no
correlation has ever been demonstrated between MET PET and
survival or between a combination of both tracers and survival.
Our results suggest that both tracers bring valuable informa
tion for prognosis. FDG visual analysis alone already can
predict quite accurately the survival prognosis.
Cutoff values for tumor-to-normal brain ratios have been
proposed by different authors, but the methodology and refer
ences must be analyzed carefully. For prediction of prognosis
inside high-grade gliomas, Patronas et al. (5) used a cutoff value
of 1.4 for FDG tumor to contralateral region ratio (correspond
ing to our T/CCR ratio), but their results are not transposable
because most of their 45 cases were recurrences. Delbeke et al.
(9), on 58 untreated gliomas studied with FDG, found that
optimal cutoff value for differentiation between low- and
high-grade gliomas was 0.6 for tumor-to-fronto-parietal CTX
ratio and 1.5 for the T/WM ratio. No cutoff level was proposed
between Grades III and IV gliomas (9).
Our FDG cutoff levels grossly correspond to differentiation
between Grades II and III gliomas (T/MCUFDG ratio = 0.8) and
between Grades III and IV gliomas (T/MCUFDG ratio = 1.1).
However, some low-grade gliomas exhibited a T/MCUFDG ratio
higher than 0.8: the two Grade II oligodendroglioma patients,
the JPA patient and another patient with a Grade II astrocytoma
who died 16 mo later (clinical evolution corresponding more to
a Grade III astrocytoma). Among low-grade gliomas with a
T/MCUFDG ratio between 0.6 and 0.8, there were three cases
with a small tumor within the CTX (T/MCU overestimated by
partial volume effect) and another Grade II astrocytoma patient,
who died 30 mo later. So, after exclusion of partial volume
effect and special histologie subgroups (especially JPA and
oligodendrogliomas), a T/MCUFDG ratio of >0.6 and, of
course, >0.8 is an indicator of malignant potential and bad
prognosis.
To our knowledge, no cutoff level has been proposed
between Grades III and IV gliomas. Our value of 1.1 was
chosen so that all tumors above this value were Grade IV
gliomas, which is meaningful in clinical practice.
Within Grade III gliomas, all astrocytomas and oligoastrocy
tomas had a T/MCUFDG ratio between 0.8 and 1.1 (75% died),
whereas the Grade III oligodendrogliomas had a ratio of <0.8
(both patients are alive).
One glioblastoma exhibited a T/MCUFDG ratio of <0.8 due
to important partial volume effect, and four cases had a ratio
between 0.8 and 1.1, but no difference in prognosis could be
demonstrated.
Only one MET cutoff level was defined by the limit between
Grade II/III and Grade IV gliomas (T/MCUMFT ratio = 2.1). No
discrimination could be made between Grades II and III
gliomas. The most difficult problem is the high MET uptake of
oligoastrocytomas and oligodendrogliomas, despite a good
prognosis.
Discriminant and Prognostic Power of MET
Compared with FDG
The discriminant power (ability, from the PET results, to
reclassify the tumors in the correct histologie grade) of MET
proved in all of the trials slightly better than that of FDG. The
addition of FDG was usually at the limit of statistical signifi
cance (p = 0.06-0.14) but improved the percentages of correct
classification.
These results could seem astonishing, considering the ineffi
ciency of MET to separate Grade III from Grade II gliomas,
which was easier with FDG. In fact, none of the Grade III
astrocytomas had PET examination with both tracers, and only
one Grade III oligodendroglioma and the case of Grade III
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oligoastrocytoma were included in this analysis. Differences
between Grade II and Grade IV gliomas were more important
with MET than with FDG. If more Grade III gliomas could have
been included, the discriminant power of FDG could have been
equivalent or superior to that of MET.
Furthermore, the choice of the T/MCU ratio could be
criticized because this ratio proved to be the best for MET but
not always for FDG. However, differences between the ratios
for FDG were small and probably did not greatly influence the
results expressed above.
Concerning the survival prognosis, the same comment can be
done concerning the small number of Grade III gliomas. This is
consistent with the results of univariate analysis, where FDG
and MET were quite equivalent (p < 0.001 for both tracers).
Actually, FDG is certainly more widely available and more
often used than MET. However, because radiosynthesis of MET
has been fully automated in our center (30), MET is used routinely
in combination with FDG in brain tumors. The most limiting factor
in clinical practice is still the short half-life of "C (20 min).
CONCLUSION
This work presents a large series of combined FDG PET and
MET PET examinations, with analysis of discriminant and
prognostic power of both tracers, analyzed individually or
together. Although both tracer uptakes are correlated clearly
and that of MET seems slightly better than that of FDG, the
combination of FDG and MET predicts the histologie grade and
the survival prognosis of gliomas better than does either alone.
Visual analysis for FDG PET and T/MCU ratios for both tracers
seem to be the best means for the evaluation of PET results.
Calculation of CMRG1 is not useful in routine clinical PET.
Besides partial volume effects (overestimation of small
low-grade cortical lesions and underestimation of necrotic or
cystic high-grade tumors), one of the most important remaining
problems is the particular metabolic behavior of specific histo
logie subgroups (i.e., JPAs and oligodendrogliomas), with a
discrepancy between a high FDG and MET uptake and a low
proliferative potential and good prognosis. These exceptions
emphasize the need to integrate PET results with all the other
clinical, radiologie and histologie information available to
select the best therapeutic procedures.
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